References
- 1. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K. CpG island methylation in Schistosomaand non-Schistosoma-associated bladder cancer. Mod Pathol. 2004; 17:1268-74.10.1038/modpathol.3800177
- 2. National Cancer Institute registry. The national cancer registry newsletter, Ministry of Health and Population, Egypt. 2002.
- 3. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol. 2006; 11:28-37.10.1007/s10147-006-0552-y
- 4. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002; 41: 284-9.10.1016/S0302-2838(02)00006-4
- 5. Eissa S, Labib RA, Swellam M, Bassiony M, Tash FM, Al-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007; 52:1388-97a.10.1016/j.eururo.2007.04.006
- 6. Eissa S, Salem AM, Zohny SF, Hegazy MG. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomarkers. 2007; 3:275-80b.
- 7. Eissa S, Swellam M, Labib RA, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by three methods: evaluation of diagnostic accuracy of bladder cancer. J Urol. 2007; 178:1068-72c.
- 8. Eissa S, Zohny SF, Swellam M, Mahmoud MH, El- Zayat TM, Salem AM. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008; 41:1335-41.
- 9. Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 2009; 181:1353-60.
- 10. Eissa S, Shabayek MI, Ismail MF, El-Allawy RM, Hamdy MA. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. IUBMB Life. 2010; 62:394-9a.
- 11. Eissa S, Swellam M, Shehata H, El-Khouly IM, El- Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol. 2010; 183:493-8b.
- 12. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol. 2010; 27:1286-91c.10.1007/s12032-009-9375-9
- 13. Eissa S, Swellam M, EL-Khouly IM, Kassim SK, Shehata H, et al. Aberrant methylation of RARb2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epid Biomark Prev. 2011; 20:1657-64.
- 14. J Parker, PE Spiess. Current and emerging bladder cancer urinary biomarkers. Science World J. 2011; 11: 1103-12.10.1100/tsw.2011.104
- 15. JA Karam, Y Lotan, SF Shariat. Bladder Cancer screening and future directions in urine-based markers for bladder urothelial carcinoma. Lab Med. 2007; 38: 116-20.10.1309/FG6FGPRLDKU3FFP4
- 16. Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Brit J Cancer. 2001; 84:1330-8.10.1054/bjoc.2001.1808
- 17. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, et al. Soluble fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer. 2006; 106:1701-7.10.1002/cncr.21795
- 18. American Joint Committee on Cancer (AJCC), Cancer staging manual. Philadelphia, Pa: Lippincott, Pa-Raven Publishers, 5th ed.; 1997.
- 19. Sobin LH, Wittkind CH. UICC TNM classification of malignant tumors, 5th ed., New York: Wiley Liss; 1997. p. 187.
- 20. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945; 101:519.10.1126/science.101.2629.519
- 21. Gui M, Idris MA, Shi YE, Muhling A, Ruppel A. Reactivity of Schistosoma japonicum and S. mansoni antigen preparations in indirect haemagglutination (IHA) with sera of patients with homologous and heterogonous schistosomiasis. Ann Trop Med Parasitol. 1991; 85:599-604.10.1080/00034983.1991.11812615
- 22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54.
- 23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiol. 1982; 143:29-36.
- 24. Eissa S, Ahmed MI, Said H, Zaghlool A, El-Ahmady O. Cell cycle regulators in bladder cancer: relationship to schistosomiasis. IUBMB Life. 2004; 56:557-64.10.1080/15216540400013903
- 25. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999; 45:1944-8.
- 26. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fasmolecule are produced by alternative splicing. J Immunol. 1995; 154: 2706-13.
- 27. Liu C, Cheng J, Mountz J. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. J Biochem. 1995; 310: 957-63.
- 28. Cheng J, Zhou T, Liu C. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263:1759-62.
- 29. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene. 1995; 10: 1157-64.
- 30. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesener TG, Bartos DP. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 1995; 94:1-8.10.1016/0304-3835(95)03834-J
- 31. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: Implication for tumor immune escape. Science. 1996; 274:1363-6.
- 32. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing’s sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 1998; 153:1947-56.
- 33. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, et al. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer. 2010; 10:275-9.10.1186/1471-2407-10-275
- 34. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006; 24:326-37.10.1016/j.urolonc.2005.11.023